HRP20220811T1 - Agonistička sredstva za vezanje tnf receptora - Google Patents
Agonistička sredstva za vezanje tnf receptora Download PDFInfo
- Publication number
- HRP20220811T1 HRP20220811T1 HRP20220811TT HRP20220811T HRP20220811T1 HR P20220811 T1 HRP20220811 T1 HR P20220811T1 HR P20220811T T HRP20220811T T HR P20220811TT HR P20220811 T HRP20220811 T HR P20220811T HR P20220811 T1 HRP20220811 T1 HR P20220811T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- amino acid
- acid sequence
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
Claims (10)
1. Bispecifično antitijelo koje sadrži najmanje dvije vezne domene, pri čemu se prva vezna domena veže za prvi receptor superfamilije faktora nekroze tumora (TNF), i druga vezna domena se veže za drugi receptor superfamilije TNF,
gdje prva vezna domena koji se veže za CD40 sadrži
(a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2323, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2324 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2325, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2326, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2327 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2328; ili
(b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2321 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2322 i gdje
druga vezna domena koji se veže za 4-1BB (CD137) sadrži
(a) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2297, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2298 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2299, i
regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2300, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2301 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2302;
(b) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2241 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2242;
(c) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2255, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2256 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2257, i
regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2258, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2259 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2260;
(d) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2227 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2228;
(e) regiju za određivanje komplementarnosti teškog lanca HCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2315, HCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2316 i HCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2317, i regiju za određivanje komplementarnosti lakog lanca LCDR1 koji ima aminokiselinsku sekvencu SEQ ID NO: 2318, LCDR2 koji ima aminokiselinsku sekvencu SEQ ID NO: 2319 i LCDR3 koji ima aminokiselinsku sekvencu SEQ ID NO: 2320; ili
(f) varijabilnu domenu teškog lanca (VH) koji ima aminokiselinsku sekvencu SEQ ID NO: 2247 i varijabilnu domenu lakog lanca (VL) koji ima aminokiselinsku sekvencu SEQ ID NO: 2248.
2. Bispecifično antitijelo prema patentnom zahtjevu 1, koje je u formatu antitijela pune dužine.
3. Bispecifično antitijelo prema patentnim zahtjevima 1 ili 2, koje sadrži jednu ili više konstantnih domena teškog lanca imunoglobulina i/ili konstantnih domena lakog lanca imunoglobulina.
4. Molekula nukleinske kiseline koja kodira bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je, poželjno, molekula nukleinske kiseline sadržana u vektoru.
5. Stanica koja sadrži molekulu nukleinske kiseline prema patentnom zahtjevu 4.
6. Farmaceutska kompozicija koja sadrži, kao aktivno sredstvo, bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, ili stanicu prema patentnom zahtjevu 5.
7. Farmaceutska kompozicija prema patentnom zahtjevu 6, koja dodatno sadrži farmaceutski prihvatljiv nosač i/ili ekscipijens.
8. Komplet koji sadrži bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanicu prema patentnom zahtjevu 5, ili farmaceutsku kompoziciju prema patentnom zahtjevu 6 ili 7.
9. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu kao lijek.
10. Bispecifično antitijelo prema bilo kojem od patentnih zahtjeva 1 do 3, molekula nukleinske kiseline prema patentnom zahtjevu 4, stanica prema patentnom zahtjevu 5, ili farmaceutska kompozicija prema patentnom zahtjevu 6 ili 7 za uporabu u liječenju bolesti odabrane iz grupe koja se sastoji od raka, infektivnih bolesti, upalnih bolesti, metaboličkih bolesti, autoimunih poremećaja i odbacivanja transplantata.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2015050255 | 2015-01-08 | ||
| EP19194817.3A EP3623386B1 (en) | 2015-01-08 | 2016-01-08 | Agonistic tnf receptor binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220811T1 true HRP20220811T1 (hr) | 2022-09-30 |
Family
ID=55072677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220811TT HRP20220811T1 (hr) | 2015-01-08 | 2016-01-08 | Agonistička sredstva za vezanje tnf receptora |
| HRP20191824TT HRP20191824T1 (hr) | 2015-01-08 | 2019-10-09 | Agonistička sredstva za vezivanje tnf receptora |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191824TT HRP20191824T1 (hr) | 2015-01-08 | 2019-10-09 | Agonistička sredstva za vezivanje tnf receptora |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US10457735B2 (hr) |
| EP (3) | EP4071176A3 (hr) |
| JP (4) | JP6744326B2 (hr) |
| KR (3) | KR102640769B1 (hr) |
| CN (3) | CN109476761B (hr) |
| AU (2) | AU2016205974B2 (hr) |
| BR (1) | BR112017013189B1 (hr) |
| CA (2) | CA2969888A1 (hr) |
| CY (1) | CY1122399T1 (hr) |
| DK (2) | DK3242890T3 (hr) |
| ES (2) | ES2755527T3 (hr) |
| HR (2) | HRP20220811T1 (hr) |
| HU (2) | HUE048532T2 (hr) |
| LT (1) | LT3623386T (hr) |
| ME (1) | ME03576B (hr) |
| MX (2) | MX377773B (hr) |
| PL (2) | PL3242890T3 (hr) |
| PT (2) | PT3242890T (hr) |
| RS (2) | RS63384B1 (hr) |
| RU (1) | RU2723131C2 (hr) |
| SG (2) | SG11201704597WA (hr) |
| SI (2) | SI3623386T1 (hr) |
| SM (2) | SMT201900702T1 (hr) |
| WO (1) | WO2016110584A1 (hr) |
| ZA (1) | ZA201704797B (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| SI2943511T1 (sl) | 2013-01-14 | 2020-01-31 | Xencor, Inc. | Novi heterodimerni proteini |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| PT3122781T (pt) | 2014-03-28 | 2020-03-05 | Xencor Inc | Anticorpos biespecíficos que se ligam a cd38 e cd3 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| AU2015353409B2 (en) | 2014-11-26 | 2019-05-09 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| CA3007233A1 (en) | 2015-12-02 | 2017-06-08 | Agenus Inc. | Antibodies and methods of use thereof |
| KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
| MX2018007204A (es) | 2015-12-16 | 2018-12-11 | Gritstone Oncology Inc | Identificacion, fabricacion y uso de neoantigeno. |
| CA3021618A1 (en) * | 2016-04-22 | 2017-10-26 | Alligator Bioscience Ab | Novel bispecific polypeptides against cd137 |
| HUE068801T2 (hu) | 2016-06-14 | 2025-01-28 | Xencor Inc | Bispecifikus kontrollpont-gátló antitestek |
| EP4050032A1 (en) | 2016-06-28 | 2022-08-31 | Xencor, Inc. | Heterodimeric antibodies that bind somatostatin receptor 2 |
| KR20240017129A (ko) * | 2016-07-14 | 2024-02-06 | 젠맵 에이/에스 | Cd40 및 cd137에 대한 다중특이적 항체 |
| KR20230130174A (ko) * | 2016-08-30 | 2023-09-11 | 젠코어 인코포레이티드 | 공자극 및 체크포인트 수용체에 결합하는 이중특이적 면역조절 항체 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| NZ751956A (en) | 2016-09-23 | 2022-01-28 | Merus Nv | Binding molecules that modulate a biological activity expressed by a cell |
| EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE |
| KR102725761B1 (ko) | 2017-01-20 | 2024-11-04 | 하이델베르크 파마 리서치 게엠베하 | Cd137+ 세포의 고갈을 위한 조성물 및 방법 |
| WO2018178046A1 (en) * | 2017-03-29 | 2018-10-04 | Glycotope Gmbh | Humanized anti-cd40 antibodies |
| IL272103B2 (en) | 2017-07-20 | 2024-10-01 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods of treating cancer |
| JP7290013B2 (ja) | 2017-08-04 | 2023-06-13 | ジェンマブ エー／エス | Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用 |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| WO2019045856A1 (en) * | 2017-08-28 | 2019-03-07 | Systimmune, Inc. | ANTI-CD ANTIBODIES AND METHODS OF MAKING AND USING THEM |
| WO2019075112A1 (en) | 2017-10-10 | 2019-04-18 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| WO2019094637A1 (en) | 2017-11-08 | 2019-05-16 | Xencor, Inc. | Bispecific and monospecific antibodies using novel anti-pd-1 sequences |
| CA3083097A1 (en) | 2017-11-22 | 2019-05-31 | Gritstone Oncology, Inc. | Reducing junction epitope presentation for neoantigens |
| KR102722731B1 (ko) | 2017-12-19 | 2024-10-25 | 젠코어 인코포레이티드 | 조작된 il-2 fc 융합 단백질 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| WO2019178362A1 (en) | 2018-03-14 | 2019-09-19 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| CN112867734A (zh) | 2018-04-18 | 2021-05-28 | Xencor股份有限公司 | 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途 |
| CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
| CN112955465A (zh) | 2018-07-03 | 2021-06-11 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| US11358999B2 (en) | 2018-10-03 | 2022-06-14 | Xencor, Inc. | IL-12 heterodimeric Fc-fusion proteins |
| CA3118789A1 (en) | 2018-11-06 | 2020-05-14 | Genmab A/S | Antibody formulation |
| WO2020106358A1 (en) | 2018-11-20 | 2020-05-28 | Takeda Vaccines, Inc. | Novel anti-zika virus antibodies and uses thereof |
| MX2021010390A (es) | 2019-03-01 | 2021-11-17 | Xencor Inc | Anticuerpos heterodimericos que se unen a enpp3 y cd3. |
| BR112021021165A2 (pt) | 2019-04-24 | 2022-01-04 | Heidelberg Pharma Res Gmbh | Conjugados anticorpo-fármaco de amatoxina e uso dos mesmos |
| KR20220137054A (ko) | 2020-02-04 | 2022-10-11 | 젠맵 에이/에스 | 요법에 사용하기 위한 항체 |
| JP2023519969A (ja) * | 2020-03-31 | 2023-05-15 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | リソソーム蓄積症に関するプロテオミクススクリーニング |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| US20230400471A1 (en) * | 2020-10-15 | 2023-12-14 | Bioincept, Llc | Systems, compositions and methods of determining viability of embryos using the same |
| CN112175080B (zh) * | 2020-10-22 | 2021-05-25 | 优睿赛思(武汉)生物科技有限公司 | 抗人白介素-6高亲和力兔单克隆抗体及应用 |
| IL303424A (en) | 2020-12-07 | 2023-08-01 | Genmab As | Antibody and taxane combination therapy |
| IL305736A (en) | 2021-03-09 | 2023-11-01 | Xencor Inc | Heterodimeric antibodies that bind CD3 and CLDN6 |
| MX2023010512A (es) * | 2021-03-09 | 2023-12-08 | Genmab As | Agentes de union multiespecificos contra cd40 y cd137 en terapia. |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
| AU2022255506A1 (en) | 2021-04-08 | 2023-11-09 | Marengo Therapeutics, Inc. | Multifunctional molecules binding to tcr and uses thereof |
| WO2022268740A1 (en) | 2021-06-21 | 2022-12-29 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
| WO2024050318A1 (en) * | 2022-08-27 | 2024-03-07 | H. Lee Moffitt Cancer Center And Research Institute | Cd40l 41bbl bispecific proteins |
| WO2024235862A1 (en) | 2023-05-12 | 2024-11-21 | Genmab A/S | Antibodies capable of binding to ox40, variants thereof and uses thereof |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| CN118440198B (zh) * | 2024-04-03 | 2024-11-15 | 武汉爱博泰克生物科技有限公司 | 抗人cd69蛋白的兔单克隆抗体及其应用 |
| CN118620078B (zh) * | 2024-07-09 | 2024-11-19 | 武汉爱博泰克生物科技有限公司 | 抗人cd45ra蛋白的抗体、抗体偶联物及其应用 |
| CN118453854B (zh) * | 2024-07-12 | 2024-10-29 | 广州粤华制药有限公司 | 一种用于建立慢性肾小球肾病模型的组合物及其应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2467242A1 (en) * | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| CN101023102B (zh) * | 2004-09-17 | 2013-05-29 | 霍夫曼-拉罗奇有限公司 | 抗-ox40l抗体 |
| CA2646508A1 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| CN101668776A (zh) | 2007-02-27 | 2010-03-10 | 健泰科生物技术公司 | 拮抗剂ox40抗体及其在炎性和自身免疫疾病的治疗中的用途 |
| EP2139924B1 (en) | 2007-03-29 | 2016-07-06 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| PT2201100E (pt) | 2007-09-14 | 2016-06-03 | Univ Brussel Vrije | Aperfeiçoamento da capacidade estimulatória de células t das células que apresentam antígeno humano e o seu uso na vacinação |
| SI2594590T1 (sl) * | 2007-12-14 | 2015-03-31 | Bristol-Myers Squibb Company | Postopek za izdelavo vezavnih molekul za humani receptor OX40 |
| US9931386B2 (en) * | 2008-06-16 | 2018-04-03 | Atsuo Ochi | Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity |
| EP2398498B1 (en) | 2009-02-17 | 2018-09-05 | UCB Biopharma SPRL | Antibody molecules having specificity for human ox40 |
| AU2011275749C1 (en) | 2010-07-09 | 2015-09-17 | Aduro Biotech Holdings, Europe B.V. | Agonistic antibody to CD27 |
| WO2012095412A1 (en) * | 2011-01-10 | 2012-07-19 | Ct Atlantic Ltd. | Combination therapy including tumor associated antigen binding antibodies |
| BR112014000630A2 (pt) | 2011-07-11 | 2017-02-14 | Glenmark Pharmaceuticals Sa | anticorpo antagonista ou fragmento do mesmo que se liga a uma ox40 humana, epítopo sobre o domínio extracelular ox40 humano, ácido nucleíco isolado, vetor, célula hospedeira, método para produzir um anticorpo ou fragmento do mesmo, composição imunoconjugado, método para tratar um distúrbio mediado por ox40 em um indivíduo, uso de um anticorpo ou fragmento do mesmo, artigo de manufatura, kit e método para classificação in vitro |
| CN103946238B (zh) * | 2011-08-23 | 2016-10-12 | 德克萨斯州立大学董事会 | 抗ox40抗体及使用其的方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| HUE040234T2 (hu) * | 2013-03-18 | 2019-02-28 | Biocerox Prod Bv | Humanizált anti-CD134 (OX40) antitestek és felhasználásaik |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| KR20240017129A (ko) * | 2016-07-14 | 2024-02-06 | 젠맵 에이/에스 | Cd40 및 cd137에 대한 다중특이적 항체 |
-
2016
- 2016-01-08 PL PL16700136T patent/PL3242890T3/pl unknown
- 2016-01-08 KR KR1020217009922A patent/KR102640769B1/ko active Active
- 2016-01-08 RS RS20220653A patent/RS63384B1/sr unknown
- 2016-01-08 PT PT167001361T patent/PT3242890T/pt unknown
- 2016-01-08 CN CN201680005119.5A patent/CN109476761B/zh active Active
- 2016-01-08 RU RU2017127792A patent/RU2723131C2/ru active
- 2016-01-08 SI SI201631557T patent/SI3623386T1/sl unknown
- 2016-01-08 HR HRP20220811TT patent/HRP20220811T1/hr unknown
- 2016-01-08 KR KR1020177021592A patent/KR102238326B1/ko active Active
- 2016-01-08 PT PT191948173T patent/PT3623386T/pt unknown
- 2016-01-08 SM SM20190702T patent/SMT201900702T1/it unknown
- 2016-01-08 LT LTEP19194817.3T patent/LT3623386T/lt unknown
- 2016-01-08 JP JP2017554647A patent/JP6744326B2/ja active Active
- 2016-01-08 SG SG11201704597WA patent/SG11201704597WA/en unknown
- 2016-01-08 US US15/538,419 patent/US10457735B2/en active Active
- 2016-01-08 HU HUE16700136A patent/HUE048532T2/hu unknown
- 2016-01-08 WO PCT/EP2016/050308 patent/WO2016110584A1/en active Application Filing
- 2016-01-08 KR KR1020247005611A patent/KR20240028548A/ko active Pending
- 2016-01-08 EP EP22167212.4A patent/EP4071176A3/en active Pending
- 2016-01-08 HU HUE19194817A patent/HUE059219T2/hu unknown
- 2016-01-08 SM SM20220288T patent/SMT202200288T1/it unknown
- 2016-01-08 CN CN202311416068.3A patent/CN117843799A/zh active Pending
- 2016-01-08 ME MEP-2019-278A patent/ME03576B/me unknown
- 2016-01-08 CA CA2969888A patent/CA2969888A1/en active Pending
- 2016-01-08 CN CN201911288299.4A patent/CN111499752B/zh active Active
- 2016-01-08 SI SI201630421T patent/SI3242890T1/sl unknown
- 2016-01-08 DK DK16700136.1T patent/DK3242890T3/da active
- 2016-01-08 EP EP16700136.1A patent/EP3242890B1/en active Active
- 2016-01-08 SG SG10202003171TA patent/SG10202003171TA/en unknown
- 2016-01-08 CA CA3224830A patent/CA3224830A1/en active Pending
- 2016-01-08 PL PL19194817.3T patent/PL3623386T3/pl unknown
- 2016-01-08 RS RS20191503A patent/RS59693B1/sr unknown
- 2016-01-08 AU AU2016205974A patent/AU2016205974B2/en active Active
- 2016-01-08 EP EP19194817.3A patent/EP3623386B1/en active Active
- 2016-01-08 DK DK19194817.3T patent/DK3623386T3/da active
- 2016-01-08 ES ES16700136T patent/ES2755527T3/es active Active
- 2016-01-08 BR BR112017013189-7A patent/BR112017013189B1/pt active IP Right Grant
- 2016-01-08 ES ES19194817T patent/ES2922398T3/es active Active
- 2016-01-08 MX MX2017008917A patent/MX377773B/es active IP Right Grant
-
2017
- 2017-07-05 MX MX2020012240A patent/MX2020012240A/es unknown
- 2017-07-14 ZA ZA2017/04797A patent/ZA201704797B/en unknown
-
2019
- 2019-09-25 US US16/582,534 patent/US10927181B2/en active Active
- 2019-10-09 HR HRP20191824TT patent/HRP20191824T1/hr unknown
- 2019-11-13 CY CY20191101191T patent/CY1122399T1/el unknown
-
2020
- 2020-07-30 JP JP2020129222A patent/JP6950056B2/ja active Active
-
2021
- 2021-01-08 US US17/144,591 patent/US11814411B2/en active Active
- 2021-09-22 JP JP2021153986A patent/JP7390345B2/ja active Active
-
2022
- 2022-01-28 AU AU2022200571A patent/AU2022200571B2/en active Active
-
2023
- 2023-04-04 JP JP2023060755A patent/JP7487376B2/ja active Active
- 2023-10-05 US US18/481,578 patent/US20240254249A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220811T1 (hr) | Agonistička sredstva za vezanje tnf receptora | |
| HRP20192098T1 (hr) | Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene | |
| JP2022177090A5 (hr) | ||
| HRP20180269T1 (hr) | Anti-cd40 protutijela, upotrebe i postupci | |
| HRP20170815T1 (hr) | Agonisti receptora 1 fibroblastnog čimbenika rasta i postupci uporabe | |
| HRP20201432T1 (hr) | Il-17a sredstvo za vezivanje i njegove uporabe | |
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| HRP20240719T1 (hr) | Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba | |
| HRP20200390T1 (hr) | Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma) | |
| HRP20200174T1 (hr) | Antitijela antigena 2 anti-krvne dendritične stanice i njihova uporaba | |
| HRP20140108T1 (hr) | Protutijela protiv sklerostina | |
| HRP20221041T1 (hr) | Anti-pd-1 antitijela i sastavi | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| IL299072A (en) | Antibodies and methods of use thereof | |
| HRP20191277T1 (hr) | Anti-cd26 antitijela i njihove primjene | |
| JP2015535828A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
| JP2017113019A5 (hr) | ||
| RU2015144105A (ru) | Антитела к гепсидину и их применения | |
| HRP20221088T1 (hr) | Protutijela i postupci uporabe | |
| RU2016138744A (ru) | Антитела, фармацевтические композиции и их применения | |
| JP2016512214A5 (hr) | ||
| RU2015102069A (ru) | Антитела к биотину и способы их применения | |
| CO2018001256A2 (es) | Anticuerpos anti-cd154 y métodos para producir los mismos |